Bad Vilbel, February 25, 2017 –

This weekend, the Executive and Supervisory Boards of STADA Arzneimittel AG have converted the ongoing open-minded talks with all interested parties started on 13 February into a structured bidding process. The transparent and fair process which is open to further interested parties ensures that all potential bidders receive the same level of information and will have the same opportunity to present their plans for STADA. For this purpose, a data room has been established and the potential bidders – three to date – have been invited to conduct multistage due diligence.

In the interest of all shareholders and stakeholders of the Company, further potential for value enhancement shall be presented in this process in order to be reflected in possible offer prices. Moreover, the value of the strategic concepts of the interested parties as well as their willingness to grant protective mechanisms for stakeholders will also be examined. The Executive and Supervisory Boards intend to conduct a thorough process that will be finalized efficiently to the best interest of the Company. STADA will keep the capital market regularly updated on tangible developments.


About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2015, STADA achieved Group sales of Euro 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 389.4 million and adjusted net income of Euro 165.8 million. As of December 31, 2015, STADA employed 10,532 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de